The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression

Wspolczesna Onkologia

Volumn 17, Issue 2, 2013, Pages 113-119

  Kołodziejczyk, Joanna ^a   Ponczek, Michał B ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Fibrin; Fibrinogen; Metastasis; Plasmin; Tumor

Indexed keywords

FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN;

ANGIOGENESIS; BLOOD CLOTTING; BREAST CANCER; CANCER GROWTH; CHEMICAL STRUCTURE; COLORECTAL CANCER; DISSEMINATED INTRAVASCULAR CLOTTING; ESOPHAGUS CANCER; FIBRINOGEN METABOLISM; HUMAN; LUNG CANCER; NONHUMAN; OVARY CANCER; PROTEIN DEGRADATION; REVIEW; STOMACH CANCER; TUMOR GROWTH; UTERINE CERVIX CANCER;

EID: 84877759638     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2013.34611     Document Type: Review

References (60)

1. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res 2001; 102: 187-94.
2. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol 2002; 3: 27-34.
3. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol 2009; 22: 49-60.
4. Kvolik S, Jukic M, Matijevic M, Marjanovic K, Glavas-Obrovac L. An overview of coagulation disorders in cancer patients. Surg Oncol 2010; 19: 33-46.
5. Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4: 465-73.
6. Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans 2002; 30: 201-7.
7. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
8. Blombäck B. Fibrinogen and fibrin - proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996; 83: 1-75.
9. Doolittle RF, Kollman JM. Natively unfolded regions of the vertebrate fibrinogen molecule. Proteins 2006; 63: 391-7.
10. Fu Y, Weissbach L, Plant PW, et al. Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: a novel exon conferring marked homology to beta and gamma subunits. Biochemistry 1992; 31: 11968-72.
11. Fu Y, Grieninger G. Fib420: a normal human variant of fibrinogen with two extended alpha chains. Proc Natl Acad Sci U S A 1994; 91: 2625-8.
12. Doolittle RF, Spraggon G, Everse SJ. Evolution of vertebrate fibrin formation and the process of its dissolution. Ciba Found Symp 1997; 212: 4-17.
13. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-72.
14. Mielicki WP, Mielicka E, Gordon SG. Cancer procoagulant activity studies using synthetic chromogenic substrates. Thromb Res 1997; 87: 251-6.
15. Mielicki WP, Tenderenda M, Rutkowski P, Chojnowski K. Activation of blood coagulation and the activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett 1999; 146: 61-6.
16. Cavanaugh PG, Sloane BF, Bajkowski AS, Taylor JD, Honn KV. Purification and characterization of platelet aggregating activity from tumor cells: copurification with procoagulant activity. Thromb Res 1985; 37: 309-26.
17. Chelladurai M, Honn KV, Walz DA. HLA-DR is a procoagulant. Biochem Biophys Res Commun 1991; 78: 467-73.
18. Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999; 25: 173-82.
19. Gaffney PJ. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann N Y Acad Sci 2000; 936: 594-610.
20. Pizzo SV, Schwartz ML, Hill RL, McKee PA. The effect of plasmin on the subunit structure of human fibrinogen. J Biol Chem 1972; 247: 636-45.
21. Furlan M, Rupp C, Beck EA. Inhibition of fibrin polymerization by fragment D is affected by calcium, Gly-Pro-Arg and Gly-His-Arg. Biochem Biphys Acta 1983; 742: 25-32.
22. Wang X, Wang E, Kavanagh JJ, Freedman RS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005; 3: 25.
23. Morganti M, Carpi A, Nicolini A, et al. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed Pharmacother 2002; 56: 317-24.
24. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-72.
25. Even-Ram S, Uziely B, Cohen P, et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 1998; 4: 909-14.
26. Palatyńska-Ulatowska A, Michalska M, Michalski Ł, Pawlicka H. Trombina i fibryna w procesach angiogenezy tkanek zebów i przyzebia - przeglad piśmiennictwa. Dent Med Probl 2007; 44: 307-13.
27. Contrino J, Goralnick S, Qi J, Hair G, Rickles FR, Kreutzer DL. Fibrin induction of tissue factor expression in human vascular endothelial cells. Circulation 1997; 96: 605-13.
28. Lalla RV, Goralnick SJ, Tanzer ML, Kreutzer DL. Fibrin induces IL-8 expressionfrom human oral squamous cell carcionoma cells. Oral Oncol 2001; 37: 234-42.
29. Guo F, Liu J, Wang C, Liu N, Lu P. Fibrinogen, fibrin, and FDP induce C-reactive protein generation in rat vascular smooth muscle cells: pro-inflammatory effect on atherosclerosis. Biochem Biophys Res Commun 2009; 390: 942-6.
30. Morganti M, Carpi A, Nicolini A, et al. Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomed Pharmacother 2002; 56: 317-24.
31. Brodt P, Fallavollita L, Bresalier RS, Meterissian S, Norton CR, Wolitzky BA. Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasis. Int J Cancer 1997; 71: 612-9.
32. Zaifert K, Cohen MC. COLO 205 utilizes E-selectin to adhere to human endothelium. Clin Immunol Immunopathol 1993; 68: 51-6.
33. Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-300.
34. Möhle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997; 94: 663-8.
35. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
36. Paduch R. Przerzut nowotworowy - znaczenie agregacji komórek nowotworowych z płytkami krwi. Onkol Pol 2005; 8: 229-38.
37. Łojko A, Zawilska K, Grodecka-Gazdecka S, Komarnicki M. Zaburzenia hemostazy a nasilenie procesu neoangiogenezy u chorych na raka piersi. Wspolczesna Onkol 2006; 10: 515-20.
38. Bootle-Wilbraham CA, Tazzyman S, Thompson WD, Stirk CM, Lewis CE. Fibrin fragment E stimulates the proliferation, migration and differentiation of human microvascular endothelial cells in vitro. Angiogenesis 2001; 4: 269-75.
39. Dejana E, Languino LR, Polentarutti N, et al. Interaction between fibrinogen and cultured endtothelial cells. Induction of migration and specific binding. J Clin Invest 1985; 75: 11-8.
40. Verheul HM, van Erp K, Homs MY, et al. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology 2010; 75: 608-14.
41. Kim KT, Choi HH, Steinmetz MO, et al. Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. J Biol Chem 2005; 280: 20126-31.
42. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiopoietin is associated with activation of Tie2. Cardiovasc Res 2001; 49: 659-70.
43. Honoré C, Rørvig S, Munthe-Fog L, Hummelshøj T, Madsen HO, Borregaard N, Garred P. The innate pattern recognition molecule Ficolin- 1 is secreted by monocytes/macrophages and is circulating in human plasma. Mol Immunol 2008; 45: 2782-9.
44. Tanio M, Kondo S, Sugio S, Kohno T. Trivalent recognition unit of innate immunity system: crystal structure of trimeric human M-ficolin fibrinogen- like domain. J Biol Chem 2007; 282: 3889-95.
45. Tucker RP, Drabikowski K, Hess JF, Ferralli J, Chiquet-Ehrismann R, Adams JC. Phylogenetic analysis of the tenascin gene family: evidence of origin early in the chordate lineage. BMC Evol Biol 2006; 6: 60.
46. Rybarczyk BJ, Simpson-Haidaris PJ. Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells. Cancer Res 2000; 60: 2033-9.
47. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis is diminished in fibrinogendeficient mice. Cancer Res 2002; 62: 6966-72.
48. Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, Bugge TH. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000; 96: 3302-9.
49. Yamashita H, Kitayama J, Kanno N, Yatomi Y, Nagawa H. Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. BMC Cancer 2006; 6: 147-53.
50. Takeuchi H, Ikeuchi S, Kitagawa Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 2007; 22: 2222-7.
51. Polterauer S, Seebacher V, Hefler-Frischmuth K, Grimm C, Heinze G, Tempfer C, Reinthaller A, Hefler L. Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol 2009; 200: 647.e1-7.
52. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003; 124: 58S-68S.
53. Biggerstaff JP, Seth N, Amirkhosravi A, Amaya M, Fogarty S, Meyer TV, Siddiqui F, Francis JL. Soluble fibrin augments platelet/tumor cell adherence in vitro and in vivo, and enhances experimental metastasis. Clin Exp Metastasis 1999; 17: 723-30.
54. Biggerstaff JP, Weidow B, Dexheimer J, Warnes G, Vidosh J, Patel S, Newman M, Patel P. Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis and immunotherapy. Clin Appl Thromb Hemost 2008; 14: 193-202.
55. Walczak B, Demkow U, Fijałkowska A.Metody oznaczania stezenia D-dimerów przydatne w diagnostyce zylnej choroby zakrzepowo- -zatorowej. Pneumonol Alergol Pol 2009; 77: 264-70.
56. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer 2003; 97: 3044-52.
57. Xu G, Zhang YL, Huang W. Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients. World J Gastroenterol 2004; 10: 922-3.
58. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002; 86: 389-95.
59. Tomimaru Y, Yano M, Takachi K, et al. Plasma D-dimer levels show correlation with number of lymph node metastases in patients with esophageal cancer. J Am Coll Surg 2006; 202: 139-45.
60. Akakura N, Hoogland C, Takada YK, Saegusa J, Ye X, Liu FT, Cheung AT, Takada Y. The COOH-terminal globular domain of fibrinogen gamma chain suppresses angiogenesis and tumor growth. Cancer Res 2006; 66: 9691-7.